Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

Standard

Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. / Zaindiutnov, Sergei S.; Kochneva, Galina; Netesov, Sergei и др.

в: Oncolytic Virotherapy, Том 8, 12.07.2019, стр. 9-26.

Результаты исследований: Научные публикации в периодических изданиях › обзорная статья › Рецензирование

BibTeX

@article{e731b3f979ac43fa99d9b04f943b8773,

title = "Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes",

abstract = "Viruses have some characteristics in common with cell-based life. They can evolve and adapt to environmental conditions. Directed evolution can be used by researchers to produce viral strains with desirable phenotypes. Through bioselection, improved strains of oncolytic viruses can be obtained that have better safety profiles, increased specificity for malignant cells, and more efficient spread among tumor cells. It is also possible to select strains capable of killing a broader spectrum of cancer cell variants, so as to achieve a higher frequency of therapeutic responses. This review describes and analyses virus adaptation studies performed with members of four RNA virus families that are used for viral oncolysis: reoviruses, paramyxoviruses, enteroviruses, and rhabdoviruses.",

keywords = "oncolytic viruses, virus selection, virus adaptation, directed viral evolution, NEWCASTLE-DISEASE VIRUS, RECOMBINANT SENDAI-VIRUS, HUMAN-MELANOMA TUMORS, VESICULAR STOMATITIS-VIRUS, OUTER CAPSID PROTEINS, SIALIC-ACID, MAMMALIAN ORTHOREOVIRUS, COXSACKIEVIRUS A21, REOVIRUS VARIANTS, IN-VIVO",

author = "Zaindiutnov, {Sergei S.} and Galina Kochneva and Sergei Netesov and Chumakov, {Peter M.} and Olga Matveeva",

year = "2019",

month = jul,

day = "12",

doi = "10.2147/OV.S176523",

language = "English",

volume = "8",

pages = "9--26",

journal = "Oncolytic Virotherapy",

issn = "2253-1572",

publisher = "Dove Medical Press Ltd.",

}

RIS

TY - JOUR

T1 - Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

AU - Zaindiutnov, Sergei S.

AU - Kochneva, Galina

AU - Netesov, Sergei

AU - Chumakov, Peter M.

AU - Matveeva, Olga

PY - 2019/7/12

Y1 - 2019/7/12

N2 - Viruses have some characteristics in common with cell-based life. They can evolve and adapt to environmental conditions. Directed evolution can be used by researchers to produce viral strains with desirable phenotypes. Through bioselection, improved strains of oncolytic viruses can be obtained that have better safety profiles, increased specificity for malignant cells, and more efficient spread among tumor cells. It is also possible to select strains capable of killing a broader spectrum of cancer cell variants, so as to achieve a higher frequency of therapeutic responses. This review describes and analyses virus adaptation studies performed with members of four RNA virus families that are used for viral oncolysis: reoviruses, paramyxoviruses, enteroviruses, and rhabdoviruses.

AB - Viruses have some characteristics in common with cell-based life. They can evolve and adapt to environmental conditions. Directed evolution can be used by researchers to produce viral strains with desirable phenotypes. Through bioselection, improved strains of oncolytic viruses can be obtained that have better safety profiles, increased specificity for malignant cells, and more efficient spread among tumor cells. It is also possible to select strains capable of killing a broader spectrum of cancer cell variants, so as to achieve a higher frequency of therapeutic responses. This review describes and analyses virus adaptation studies performed with members of four RNA virus families that are used for viral oncolysis: reoviruses, paramyxoviruses, enteroviruses, and rhabdoviruses.

KW - oncolytic viruses

KW - virus selection

KW - virus adaptation

KW - directed viral evolution

KW - NEWCASTLE-DISEASE VIRUS

KW - RECOMBINANT SENDAI-VIRUS

KW - HUMAN-MELANOMA TUMORS

KW - VESICULAR STOMATITIS-VIRUS

KW - OUTER CAPSID PROTEINS

KW - SIALIC-ACID

KW - MAMMALIAN ORTHOREOVIRUS

KW - COXSACKIEVIRUS A21

KW - REOVIRUS VARIANTS

KW - IN-VIVO

U2 - 10.2147/OV.S176523

DO - 10.2147/OV.S176523

M3 - Review article

C2 - 31372363

VL - 8

SP - 9

EP - 26

JO - Oncolytic Virotherapy

JF - Oncolytic Virotherapy

SN - 2253-1572

ER -

ID: 23649243